AcouSort AB (4SA) Price & Analysis

0 Followers

4SA Stock Chart & Stats

€0.30

>-€0.01(-0.99%)

At close: Jul 24 4:00 PM EDT

€0.30

>-€0.01(-0.99%)

Day’s Range― - ―

52-Week Range€0.12 - €0.41

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€6.86M

Enterprise Value€75.16M

Total Cash (Recent Filing)€14.57M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.06

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.49

Shares Outstanding21,163,902

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.12

Price to Book (P/B)3.27

Price to Sales (P/S)7.79

P/FCF Ratio-3.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.03

Revenue Forecast (FY)€983.98K

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero reported debt provides durable financial flexibility: it lowers solvency risk, preserves borrowing capacity, and reduces fixed interest obligations. Over 2-6 months this supports continued R&D and commercialization spending without immediate refinancing pressure, improving strategic optionality.

Improving Revenue GrowthSustained top-line improvement indicates growing commercial traction for AcouTrap and related offerings. Over the medium term, consistent revenue growth supports operating scale, can enable margin recovery if cost structure is managed, and validates market demand in diagnostics and cell-therapy workflows.

Proprietary Acoustic Separation TechnologyAcuSort's acoustophoresis platform is a structural competitive asset: gentle, label-free separation suits sensitive cell-therapy and diagnostic use-cases. This differentiation can create durable product-market fit, higher switching costs and long-term revenue streams from lab and clinical integrations.

Bears Say

Negative Gross Profit And Persistent LossesSustained negative gross profit and large operating losses indicate the core offering is not yet economically scalable. Without improving product margin or pricing, loss-making operations will continue to erode capital and limit ability to invest in commercialization or meet regulatory/commercial milestones.

Negative Free Cash Flow And Inconsistent Cash GenerationMaterial negative operating and free cash flow create a persistent funding need. Over months the company may require additional capital or partnerships to sustain operations, constraining strategic choices and increasing dilution or dependency on external financing for commercialization and scale-up.

Eroding Equity And Very Weak ReturnsSteep negative ROE and declining equity signal poor capital efficiency and persistent value destruction. This undermines long-term investor confidence, limits internal funding options, and increases the likelihood of dilutive capital raises if operational performance doesn't improve.

4SA FAQ

What was AcouSort AB’s price range in the past 12 months?

AcouSort AB lowest stock price was €0.12 and its highest was €0.41 in the past 12 months.

What is AcouSort AB’s market cap?

AcouSort AB’s market cap is €6.86M.

When is AcouSort AB’s upcoming earnings report date?

AcouSort AB’s upcoming earnings report date is Aug 26, 2026 which is in 27 days.

How were AcouSort AB’s earnings last quarter?

AcouSort AB released its earnings results on May 27, 2026. The company reported -€0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.01.

Is AcouSort AB overvalued?

According to Wall Street analysts AcouSort AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AcouSort AB pay dividends?

AcouSort AB does not currently pay dividends.

What is AcouSort AB’s EPS estimate?

AcouSort AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AcouSort AB have?

AcouSort AB has 21,163,902 shares outstanding.

What happened to AcouSort AB’s price movement after its last earnings report?

AcouSort AB reported an EPS of -€0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.444%.

Which hedge fund is a major shareholder of AcouSort AB?

Currently, no hedge funds are holding shares in DE:4SA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AcouSort AB

AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an module that enables in-line analysis of blood plasma from whole blood samples; AQC Module, an in-line optical analysis of particle suspensions for quality control or monitoring applications; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company has collaboration agreement with global life science company to develop cell therapy and other elements of the future automated systems. AcouSort AB (publ) was founded in 2010 and is based in Lund, Sweden.